Sequent Scientific Limited has informed the Exchange about Presentation
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific reported Q1 FY26 consolidated revenue of ₹4,414 million, up 13.1% year-on-year, driven by broad-based growth across Formulations and APIs. Adjusted EBITDA rose 24.7% to ₹602 million with margins expanding 126 basis points to 13.6%, and profit after tax nearly doubled to ₹176 million (+93.7% YoY). The company is progressing on its proposed merger with Viyash Life Sciences, having received CCI and stock exchange approvals, with NCLT directing a shareholder and creditor meeting on August 30, 2025, and the deal expected to close within 12–15 months of the September 2024 announcement. On a combined pro-forma basis, Q1 FY26 revenue stood at ₹7,941 million with EBITDA margin of 16.2% and net debt to LTM EBITDA improving to 0.6x from 1.0x in Q4 FY25. Management has begun work on the 'Sequent 3.0' roadmap to capture post-merger synergies in R&D, manufacturing, sales, and administration.
Strong quarterly earnings with healthy margin expansion and a clearly progressing merger are positive signals for shareholders; the improving leverage profile and synergy plans could support continued stock momentum, though the deal remains subject to final NCLT and other regulatory approvals.